BusinessSwitzerlandUK

Atlas of cancer cell drug sensitivity launched

30.03.2012 - Two European teams have created huge repositories of cancer genomics data that help predict drug response.

Swiss Novartis and the Boston-based Broad Institute have combined data obtained from large-scale sequencing data of 947 of the 1,200 commercially available human cancer cell lines with the pharmacological profiles of 24 anti-cancer drugs. (Nature 29 March) in a „Cancer Cell Line Encyclopaedia (CCLE)". The cell lines reflect the genetic disturbances that drive cancers,“ said Mark Fishman, Chief of the Novartis Institutes for BioMedical Research (NIBR) that led the study. „Probing cell lines with medicines targeted at specific pathways, as done for the CCLE, provides a powerful tool for design of cancer treatment.“ The data, put into the public domain, will help improve developing targeted therapies. The CCLE provides gene expression data, information on copy number changes as well as DNA sequence variations in about 1,600 cancer-related genes. Additionally, algorithms have been developed to predict drug responses based on the cancer cell’s molecular make-up. When a personal genome is matched against these data an optimised therapy can be obtained for this patient.

In a second study, European researchers from the cancer genome project teamed (coordination EBI, Hinxton) up with US doctors from Massachusetts General Hospital to uncover genetic biomarkers of cancer cells’ drug sensitivity against 130 compounds under clinical and preclinical development (Nature 29.3.). The study was carried out analysing 630 human tumour cell lines representing cancers of epthelial, mesenchymal and hematopoetic origin. The identified cancer subtypes and drug response profiles have been put to the public domain to help researchers engaged in the development of personalised cancer treatments. 

http://www.european-biotechnology-news.com/news/news/2012-01/atlas-of-cancer-cell-drug-sensitivity-launched.html

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

BusinessPolandUK

01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.

R&DUKIreland

29.07.2016 GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLMED (I)0.39 EUR11.43%
  • CERENIS THERAPEUTICS HOLDING SA (F)7.51 EUR10.77%
  • SYNGENTA (CH)421.20 CHF10.61%

FLOP

  • RENEURON (UK)2.62 GBP-9.03%
  • BIONOR PHARMA (N)0.48 NOK-7.69%
  • ZEALAND PHARMA (DK)113.50 DKK-6.58%

TOP

  • DIAMYD MEDICAL -B- (S)7.15 SEK70.2%
  • KARO BIO (S)37.80 SEK31.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.80 SEK25.0%

FLOP

  • BIONOR PHARMA (N)0.48 NOK-21.3%
  • NOVOZYMES (DK)286.90 DKK-13.5%
  • RENEURON (UK)2.62 GBP-12.7%

TOP

  • KARO BIO (S)37.80 SEK2420.0%
  • NICOX (F)10.12 EUR459.1%
  • SAREUM HOLDINGS (UK)0.76 GBP261.9%

FLOP

  • BB BIOTECH (D)45.12 EUR-81.0%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NOVACYT (F)1.29 EUR-70.6%

No liability assumed, Date: 23.08.2016